Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection (Q40925274)

24 September 2017

Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection (English)

1 reference

24 September 2017

Young-In Kim

1

1 reference

24 September 2017

Jae-Hyoung Song

2

1 reference

24 September 2017

Bo-Eun Kwon

3

1 reference

24 September 2017

Ha-Neul Kim

4

1 reference

24 September 2017

Min-Duk Seo

5

1 reference

24 September 2017

KwiSung Park

6

1 reference

24 September 2017

SangWon Lee

7

1 reference

24 September 2017

Sang-Gu Yeo

8

1 reference

24 September 2017

Mi-Na Kweon

9

1 reference

24 September 2017

Hyun-Jeong Ko

10

1 reference

24 September 2017

Sun-Young Chang

11

1 reference

24 September 2017

language of work or name

English

0 references

publication date

31 October 2015

1 reference

24 September 2017

1 reference

24 September 2017

33

1 reference

24 September 2017

48

1 reference

24 September 2017

6604-6610

1 reference

Antiviral activity of ginsenosides against coxsackievirus B3, enterovirus 71, and human rhinovirus 3.

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Antiviral Activity of Hederasaponin B from Hedera helix against Enterovirus 71 Subgenotypes C3 and C4a.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Characterization of the enterovirus 71 VP1 protein as a vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

An inactivated enterovirus 71 vaccine in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Identification of a human SCARB2 region that is important for enterovirus 71 binding and infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Virus-like particles in vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

DNA vaccine constructs against enterovirus 71 elicit immune response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Placental transport of immunoglobulin G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

FcRn: the neonatal Fc receptor comes of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

The immune response and maternal antibody interference to a heterologous H1N1 swine influenza virus infection following vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Studies on the mechanism by which antigen-specific IgG suppresses primary antibody responses: evidence for epitope masking and decreased localization of antigen in the spleen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

FcgammaRIIB in IgG-mediated suppression of antibody responses: different impact in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Pre-existing immunity against vaccine vectors--friend or foe?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Performance of rotavirus vaccines in developed and developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

Transgenic mouse model for the study of enterovirus 71 neuropathogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.103

10.1016/J.VACCINE.2015.10.103

7 January 2021

Identifiers

DOI

1 reference

24 September 2017

1 reference